TP 12
Alternative Names: ATP 012Latest Information Update: 05 Jun 2002
At a glance
- Originator AstraZeneca; AVANT Immunotherapeutics
- Developer AVANT Immunotherapeutics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 05 Jun 2002 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 02 Apr 1997 Preclinical development for Multiple sclerosis in USA (Unknown route)